IRIS
PARENTI, Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.880
AS - Asia 3.068
EU - Europa 3.051
SA - Sud America 568
AF - Africa 539
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 16.122
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.610
SG - Singapore 1.399
CN - Cina 1.144
IT - Italia 1.036
IE - Irlanda 615
UA - Ucraina 536
BR - Brasile 501
CI - Costa d'Avorio 374
CA - Canada 234
RU - Federazione Russa 190
DE - Germania 188
VN - Vietnam 128
SE - Svezia 104
SN - Senegal 103
GB - Regno Unito 88
KR - Corea 88
IN - India 68
JP - Giappone 57
FR - Francia 46
FI - Finlandia 38
ES - Italia 31
NL - Olanda 30
PL - Polonia 29
ID - Indonesia 27
MX - Messico 27
BD - Bangladesh 26
BE - Belgio 25
AR - Argentina 23
UZ - Uzbekistan 20
HK - Hong Kong 19
AT - Austria 17
CH - Svizzera 17
ZA - Sudafrica 17
TR - Turchia 16
IQ - Iraq 15
CZ - Repubblica Ceca 14
GR - Grecia 11
AU - Australia 10
BJ - Benin 10
EC - Ecuador 10
PK - Pakistan 10
AE - Emirati Arabi Uniti 8
MA - Marocco 8
CL - Cile 7
CO - Colombia 7
HU - Ungheria 7
IR - Iran 7
LB - Libano 7
VE - Venezuela 7
DZ - Algeria 6
EG - Egitto 6
LT - Lituania 6
PE - Perù 6
TH - Thailandia 6
BG - Bulgaria 5
EU - Europa 5
IL - Israele 5
AL - Albania 4
KE - Kenya 4
NG - Nigeria 4
NO - Norvegia 4
PY - Paraguay 4
SA - Arabia Saudita 4
AZ - Azerbaigian 3
TN - Tunisia 3
AO - Angola 2
BB - Barbados 2
DK - Danimarca 2
NP - Nepal 2
RS - Serbia 2
SV - El Salvador 2
UY - Uruguay 2
AM - Armenia 1
BO - Bolivia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MY - Malesia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
Totale 16.122
Salva come PNG Salva come JPEG
Città #
Dallas 1.709
Houston 1.024
Santa Clara 1.011
Chandler 794
Singapore 700
Dublin 611
Jacksonville 513
Chicago 467
Abidjan 374
Ashburn 331
Catania 331
Boardman 289
Nanjing 190
Beijing 177
Hefei 174
Cambridge 173
Lawrence 173
Andover 171
Toronto 160
Dakar 103
Los Angeles 102
Civitanova Marche 94
Wilmington 94
Seoul 88
San Mateo 87
Bremen 83
Des Moines 71
Council Bluffs 70
Nanchang 65
Columbus 52
Shenyang 52
The Dalles 51
São Paulo 50
Tokyo 50
Saint Petersburg 46
New York 45
Jiaxing 42
Ottawa 42
Rome 42
Changsha 40
Ho Chi Minh City 40
Munich 39
Tianjin 38
Hebei 34
Grafing 32
Buffalo 31
Naples 31
Hanoi 28
Brussels 24
Jakarta 19
Moscow 19
Brooklyn 18
Seattle 18
Turku 18
Warsaw 18
Denver 17
Dong Ket 17
Falls Church 17
Pune 17
Rio de Janeiro 17
Hong Kong 16
Messina 16
Atlanta 15
Jinan 15
Montreal 15
Ningbo 15
Norwalk 15
San Giovanni la Punta 14
Amsterdam 13
Augusta 13
Belo Horizonte 13
Helsinki 13
Washington 13
Johannesburg 12
Mascalucia 11
Zhengzhou 11
Boston 10
Campinas 10
Cotonou 10
London 10
Milan 10
Orem 10
Paternò 10
Phoenix 10
San Francisco 10
Kunming 9
Leawood 9
Madrid 9
Salerno 9
Salvador 9
Stockholm 9
Ann Arbor 8
Chennai 8
Fremont 8
Fuzhou 8
Haiphong 8
Liberty Lake 8
Mumbai 8
Palermo 8
Porto Alegre 8
Totale 11.669
Salva come PNG Salva come JPEG
Nome #
Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. 435
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 394
NOP RECEPTOR ANTAGONISM IN THE VENTROLATERAL PERIAQUEDUCTAL GRAY ATTENUATES THE DEVELOPMENT OF OPIOID TOLERANCE. 316
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 270
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 197
Involvement of sigma 2 receptor on motor disorder 186
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 170
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 169
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 156
Inhibition of Cx43 mediates protective effects on hypoxic/reoxygenated human neuroblastoma cells 145
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 140
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 138
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 136
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 133
A new sigma ligand, (+/-)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect 129
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 128
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 124
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 123
Connexins in the central nervous system: physiological traits and neuroprotective targets 122
CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro 121
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 118
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 116
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 116
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 112
Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands 109
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 109
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 107
Intercellular communication and ion channels in neuropathic pain chronicization 106
Sigma-2 receptor ligands QSAR model dataset 105
Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization 105
Central and peripheral control by endogenous opioid peptides of gastric protection in stressed-rats 104
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 104
From plant to bench: natural products as source for analgesic drug development. 104
Studio aerobiologico e incidenza di pollinosi nella popolazione acese 103
Chronic treatment with fluoxetine induces sex-dependent analgesic effects and modulates HDAC2 and mGlu2 expression in female mice 103
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 102
Effect of supraspinal Nocistatin on nociceptin/OrphaninFQ antagonism of selective opioid analgesia 102
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 102
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 102
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 101
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 99
Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia 98
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 97
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 97
Apoptotic effects of (±) MRJF4 in prostate cancer cells 97
MOR/DOR targeting: an useful strategy in pain management 97
(+)-Mr200 derivatives: modifications on the amino moiety. In vitro and in vivo pharmacological evaluation 96
Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na+ /Ca2+ exchanger isoform NCX3 in human neuroblastoma SH-SY5Y cells 96
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 94
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 94
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 94
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 93
Effect of CCK-8 on analgesia induced by cold-restraint stress in the rat 93
Wilms’ Tumor Gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line 93
Neuroprotective effect of the new sigma receptor ligands cis-(+) and cis-(–)-PPCC 93
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 92
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 92
Multitarget opioid ligands in pain relief: New players in an old game 91
Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype 91
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 91
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 91
Effects of dinorphin 1-13 on hyperalgesia induced by interleukin-1bera in the rat 89
ANTIALLODYNIC AND ANTIHYPERALGESIC EFFECTS OF INTRAPLANTAR NOCISTATIN AND (±)-J 113397 IN INFLAMMATORY PAIN 89
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 89
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 89
Prevention of stress-induced gastric ulcers by mu- and delta-opioid agonists in the rat. 88
Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats. 88
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 88
Preclinical evidence of enhanced analgesic activity of duloxetine complexed with succinyl-β-cyclodextrin: A comparative study with cyclodextrin complexes 88
Central and peripheral involvement of endogenous opioid peptides in gastric protection in stressed rats 87
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 86
Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain: A possible correlation with delta opiod receptors-mediated antiallodinic effect. 86
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 85
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 85
Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives 84
Wilms' tumor 1 (WT1) protein expression in human developing tissues 83
Progress in the development of more effective and safer analgesics for pain management 83
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 82
Antiallodynic and antihyperalgesic effects of intraplantar nocistatin and (+/-)-J113397 in inflammatory pain 82
Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory Pain 82
Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: Focus on microglia activation 81
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 80
Effect of centrally administered -B-endorphin on the development of stress-induced gastric ulcers in rats 80
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 80
In-vitro evaluation of a new benzomorphan-based ligand 79
Dual-target ligands and pain: our experience 78
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 78
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 78
Different in vitro activity of flurbiprofen and its enantimers on human articular cartilage 78
Stress-induced changes in the thermic effects of cholecystokinin in the rat 77
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 76
HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors 76
Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain 76
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 76
Evaluation of N-substitution in 6,7-benzomorphan compounds 76
Role of the Nrf2/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries 76
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 75
Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain 75
Inhibition of pain response in the formalin test by naloxone in normal- or cold-.restrained-rats 74
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands 74
Totale 11.017
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.418
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.418
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021812 0 0 0 0 294 35 106 8 110 16 170 73
2021/20221.382 163 178 15 38 210 16 186 56 123 23 56 318
2022/20232.419 196 127 46 291 214 378 8 439 512 45 101 62
2023/20241.265 82 218 78 62 68 286 48 76 2 33 218 94
2024/20254.084 67 747 214 236 877 480 196 188 243 321 243 272
2025/20263.824 527 340 1.908 455 594 0 0 0 0 0 0 0
Totale 16.564